Despite these limitations, the present study describes real-life C1-INH-HAE patients using different strategies for the treatment of acute attacks and may provide useful information with regard to patient subgroups most likely to benefit from self-administration. The gene discussed is SERPING1; the disease is hereditary angioedema.